Xilio Therapeutics, Inc. (NASDAQ: XLO) will present preclinical data for its masked T cell engager program targeting CLDN18.2 at the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE